IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study - Im
Imunon, Inc. (IMNN) Presents at Life Sciences Virtual Investor Forum - Slideshow (NASDAQ:IMNN) 2026-06-26